BSKB’s intellectual property attorneys write articles on important and timely topics in intellectual property law across a variety of industries. You’ll find the latest articles and industry insights here.
May 29, 2020
The April 22, 2014 decision in Gilead Sciences, Inc v Natco Pharma Inc (Gilead) emphasises that obviousness-type double patenting (ODP) is a concern not just during the examination of a patent before the US Patent and Trademark Office (USPTO) but is a viable basis for invalidating an issued patent despite the presumption of validity that a patent has under 35 USC §282. In the case, Gilead owned two patents: the ‘483 and the ‘375. After being sued for infringement of the ‘483 patent, Natco asserted that the claims of the ‘483 patent were invalid for ODP as being obvious given the claims of the ‘375 patent.